Huaheng Biotechnology: The issuance of overseas listed shares has been filed with the China Securities Regulatory Commission.

Huaheng Biology announced that the company plans to issue up to 31.9593 million overseas listed ordinary shares and list them on the Hong Kong Stock Exchange. The company has recently received a notice of filing from the China Securities Regulatory Commission. From the date of issuance of the notice of filing to the completion of the overseas issuance and listing, the company must report any significant events through the filing management information system. Within 15 working days after the issuance and listing, the company must also report on the issuance and listing situation. The overseas issuance and listing still require approval from relevant regulatory authorities and stock exchanges in Hong Kong, and there is uncertainty.